Author(s) Fonder MA, Cummins DL, Ehst BD, Anhalt GJ, Meyerle JH, et al.

Journal Journal of burns and wounds. Date of publication 2006 Nov 20;volume 5():e8.

Abstract 1. J Burns Wounds. 2006 Nov 20;5:e8. Adalimumab therapy for recalcitrant pyoderma gangrenosum. Fonder MA(1), Cummins DL, Ehst BD, Anhalt GJ, Meyerle JH. Author information: (1)Department of Dermatology, Johns Hopkins Medical Institutions, Baltimore, MD, USA. OBJECTIVE: To describe a patient with treatment-refractory pyoderma gangrenosum and the outcome of a novel therapeutic approach. METHODS: Case report and review of the literature. RESULTS: A patient with inflammatory bowel disease developed severe pyoderma gangrenosum while receiving treatment with the chimeric anti-TNF-alpha antibody infliximab. Despite subsequent trials of numerous immunosuppressive and immunomodulatory medications, the dermatologic disease progressed. The patient's ulcers finally resolved when treatment with adalimumab, a fully humanized monoclonal antibody specific for TNF-alpha, was initiated. CONCLUSIONS: We report a novel application of the TNF-alpha inhibitor, adalimumab, in the treatment of pyoderma gangrenosum. PMCID: PMC1687150 PMID: 17149453

Source ID (e.g. PMID): 17149453